A Multicenter, Open-Label Study With A Randomized Control Arm Of The Efficacy, Safety, And Pharmacokinetics Of Intravenously Infused Berubicin In Adult Patients With Recurrent Glioblastoma Multiforme (WHO Grade IV) After Failure Of Standard First Line Therapy